Vetter Pharma to Build New Manufacturing Site in Germany

The pharmaceutical CDMO will invest €480 million in a new production facility in southwest Germany.

Jan. 30, 2026 at 9:31am

Got story updates? Submit your updates here. ›

Vetter Pharma, a leading Contract Development and Manufacturing Organization (CDMO), has confirmed plans to build a new state-of-the-art production facility in the Saarland region of southwest Germany. The €480 million investment marks a significant milestone in the company's global growth strategy, with operations expected to commence in 2031 and the potential to create up to 2,000 jobs in the long term.

Why it matters

Vetter's decision to expand its manufacturing capabilities in Germany underscores the country's continued prominence as a hub for the pharmaceutical industry. The new facility will help meet growing customer demand and increase Vetter's overall production capacity, strengthening its position as a strategic partner to the global pharmaceutical market.

The details

The 95-acre industrial site in Saarlouis was acquired by Vetter at the end of 2024 after careful strategic considerations. Construction is scheduled to begin in the second quarter of 2026, with the first phase of the new commercial production plant expected to be operational by 2031. In parallel, Vetter is also building a new clinical production site in Des Plaines, Illinois, USA, further expanding its global footprint.

  • Vetter acquired the 95-acre industrial site in Saarlouis at the end of 2024.
  • Construction on the new production facility is scheduled to begin in the second quarter of 2026.
  • Operations at the new commercial production plant in Saarlouis are expected to commence in 2031.

The players

Vetter Pharma

A leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. Vetter provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges.

Udo J. Vetter

The Chairman of the Advisory Board and member of the owner family of Vetter Pharma.

Got photos? Submit your photos here. ›

What they’re saying

“With the construction of our new production facility in Germany, we continue on our path to sustainable growth. Long-term success derives from striking the right balance between stability and expansion.”

— Udo J. Vetter, Chairman of the Advisory Board and member of the owner family

What’s next

Operations at the new commercial production plant in Saarlouis are expected to commence in 2031.

The takeaway

Vetter's decision to invest €480 million in a new state-of-the-art production facility in Germany underscores the country's continued prominence as a hub for the pharmaceutical industry and Vetter's commitment to sustainable growth and expanding its global footprint.